OXFORD, England--(BUSINESS WIRE)--#chronic--Ochre Bio, an innovator in chronic liver disease drug development, today announced its participation in upcoming investor and industry conferences.
WebSummit
Presentation Title: Why you should love your liver
Date/Time: Nov 4, 1:36 WET - 1:47 pm Western European Time
Location: The Altice Arena and FIL, Rossio dos Olivais, 1990-231 Lisbon, Portugal
Presenter: Jack O�Meara, CEO & Co-Founder, Ochre Bio
Big Data and AI Innovation in Drug Discovery
Artificial Intelligence (AI) and big data approaches in drug discovery have gained substantial momentum over the past few years, with the benefit of speeding up drug development timelines as well as reducing research costs. Ochre Bio employs genomics-led target discovery and human-based preclinical models and RNA medicine to develop new therapies for chronic liver diseases. Seeing the infinite potential of AI and big data's involvement in drug development, Ochre Bio will hold a symposium in Taipei, Taiwan on this trending topic.
Date/Time: Wednesday, Nov. 9, 9:30-12:15 pm
Location: 2nd Floor, Building C, National Biotechnology Research Park , No. 99, Lane 130, Section 1, Institute Road, Nangang District, Taipei, Taiwan
Symposia Information: https://geneonline.news/ochre-bio-ai-big-data-symposium/
Agenda and registration: https://forms.gle/gQeiQaPbexY7ACqy9
Speakers include industry leaders in the field of big data, genomics and drug development:
- Dr. Quin Wills, CSO of Ochre Bio
- Dr. Jimmy Lin, CEO of Insilico Medicine Taiwan
- Dr. Inca Chen, RD Manager of Acer
- Prof Liao, CEO of Syncell
LSX Inv�$tival Showcase
Date: Monday, Nov. 14, 10:45 am - 11:00 am UK time
Location: 1 Old Billingsgate Walk, London, UK
Presenter: Jack O�Meara, CEO & Co-Founder, Ochre Bio
Jefferies London Healthcare Conference
Date: November 15-17, 2022
Location: Waldorf Hilton (Aldwych), London, UK
To meet with the Ochre Bio team at these events, [email protected].
About Ochre Bio
Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com. Follow us on Twitter @OchreBio.
Contacts
Media
Kimberly Ha
KKH Advisors
917-291-5744
[email protected]
